Premium
New drugs for non‐alcoholic steatohepatitis
Author(s) -
Cardoso AnaCarolina,
FigueiredoMendes Claudio,
A. VillelaNogueira Cristiane,
Sanyal Arun J.
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14354
Subject(s) - steatohepatitis , medicine , cirrhosis , fatty liver , hepatocellular carcinoma , alcoholic liver disease , disease , chronic liver disease , liver disease , gastroenterology , population , environmental health
Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.